Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices.

IF 1.3 4区医学 Q3 NURSING

Clinical journal of oncology nursing Pub Date : 2024-09-17 DOI:10.1188/24.CJON.1-8.AP

Shahnaz Singh-Kandah, Kaiwen Wang, Karen Xia, Andy Lain Johnson, Denise M D'Andrea, Catherine A Shu, Lindsay Bray Dougherty, Stephanie M Gallitano

{"title":"Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices.","authors":"Shahnaz Singh-Kandah, Kaiwen Wang, Karen Xia, Andy Lain Johnson, Denise M D'Andrea, Catherine A Shu, Lindsay Bray Dougherty, Stephanie M Gallitano","doi":"10.1188/24.CJON.1-8.AP","DOIUrl":null,"url":null,"abstract":"Background: Amivantamab is an epidermal growth factor receptor (EGFR) and MET bispecific antibody approved for certain patients with advanced non-small cell lung cancer with EGFR variant. Cutaneous toxicities are known on-target effects of EGFR inhibition.Objectives: This article describes the occurrence and management of cutaneous toxicities in patients whose disease progressed on platinum chemotherapy treated with amivantamab.Methods: Post hoc analysis evaluated incidence, severity, and time to first onset of rash and paronychia. Five nurses and advanced practice providers were interviewed.Findings: Of 380 patients, 296 (78%) experienced treatment-related rash and/or paronychia. Paronychia (43%), rash (36%), and dermatitis acneiform (35%) were most frequent, with scalp rash reported by 17%. Treatment modifications because of rash and paronychia were infrequent. Nurses and advanced practice providers collaborate with physicians to manage cutaneous toxicities by administering comedications, modifying amivantamab dose, and educating patients.","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical journal of oncology nursing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1188/24.CJON.1-8.AP","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NURSING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Amivantamab is an epidermal growth factor receptor (EGFR) and MET bispecific antibody approved for certain patients with advanced non-small cell lung cancer with EGFR variant. Cutaneous toxicities are known on-target effects of EGFR inhibition.

Objectives: This article describes the occurrence and management of cutaneous toxicities in patients whose disease progressed on platinum chemotherapy treated with amivantamab.

Methods: Post hoc analysis evaluated incidence, severity, and time to first onset of rash and paronychia. Five nurses and advanced practice providers were interviewed.

Findings: Of 380 patients, 296 (78%) experienced treatment-related rash and/or paronychia. Paronychia (43%), rash (36%), and dermatitis acneiform (35%) were most frequent, with scalp rash reported by 17%. Treatment modifications because of rash and paronychia were infrequent. Nurses and advanced practice providers collaborate with physicians to manage cutaneous toxicities by administering comedications, modifying amivantamab dose, and educating patients.

查看原文本刊更多论文

阿米万他单抗治疗非小细胞肺癌的皮肤毒性：实用指南与最佳实践》。

背景：阿米万他单抗是一种表皮生长因子受体（EGFR）和MET双特异性抗体，已被批准用于治疗某些EGFR变异的晚期非小细胞肺癌患者。皮肤毒性是表皮生长因子受体抑制剂已知的靶向效应：本文描述了阿米万他单抗治疗铂类化疗后病情进展患者皮肤毒性的发生和处理情况：方法：事后分析评估了皮疹和瘙痒的发生率、严重程度和首次发病的时间。结果：在 380 名患者中，有 296 人（296 例）首次出现皮疹和副皮炎：在 380 名患者中，296 人（78%）出现了与治疗相关的皮疹和/或副皮炎。皮疹（43%）、皮疹（36%）和痤疮样皮炎（35%）最为常见，头皮皮疹占 17%。因皮疹和副癣而修改治疗方案的情况并不常见。护士和高级医疗服务提供者应与医生合作，通过给患者用药、调整阿米万他单抗剂量和教育患者来控制皮肤毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical journal of oncology nursing ONCOLOGY-NURSING

CiteScore

1.70

自引率

9.10%

发文量

127

审稿时长

6-12 weeks

期刊介绍： The Clinical Journal of Oncology Nursing (CJON) is an official publication of the Oncology Nursing Society (ONS) and is directed to the practicing nurse specializing in the care of patients with an actual or potential diagnosis of cancer. CJON is a vehicle to promote the mission of ONS, which is to advance excellence in oncology nursing and quality cancer care. The CJON mission is twofold: to provide practical information necessary to care for patients and their families across the cancer continuum and to develop publication skills in oncology nurses.